QureBio, a Shanghai, China-based firm growing bispecific and multispecific antibody and protein therapeutics, raised almost CNY 100M (approx. $14M) in Collection C1 funding.
The spherical was led by Efung Capital.
The corporate intends to make use of the funds to speed up its medical trials and advance its pipeline of recent antibody therapeutics.
Based in 2017, Qure Biotechnology is a biopharmaceutical firm which specializes within the analysis and improvement of recent antibody and protein therapeutics, specializing in bispecific and multispecific antibodies for oncology, autoimmune ailments, and inflammatory issues. It has constructed a number of proprietary know-how platforms for antibody discovery and engineering, enabling a pipeline of drug candidates aimed toward addressing essential unmet medical wants in China and all over the world.
Key pipeline developments embody:
- Q-1802 (Claudin18.2/PD-L1 bispecific antibody): Acquired regulatory clearance to provoke medical trials in each China and the USA in March 2021. Section II affected person enrollment is sort of full, and preparations are underway for Section III medical trials in China.
- Q-1801 (SIRPα/PD-L1 bispecific antibody): Obtained medical trial approvals in China and the US, and is poised to start medical research.
- PD-1 Antibody-Cytokine Fusion Candidate: An modern fusion protein with twin capabilities as a PD-1 checkpoint inhibitor and a cytokine modulator, demonstrating a positive therapeutic window. This candidate targets an space the place comparable approaches by bigger biopharmaceutical firms have confronted setbacks, and QureBio is in search of companions to speed up its international improvement.
FinSMEs
05/06/2025
